About Us
Company Overview
Vision / Mission / Values
Leadership
Clinical Advisory Board
Partnering
Our Approach
Technologies
Manufacturing
Publications
Pipeline
Pipeline
Autologous CAR-T
Allogeneic CAR-T
Expanded Access
Investors
Announcements
Corporate Governance
Corporate Deck & Presentations
Webcasts
Presentations
Financial Reports
Listing Documents
IR Contact
Newsroom
Careers
Join Us
Contact Us
EN
简
About Us
Company Overview
Vision / Mission / Values
Leadership
Clinical Advisory Board
Partnering
Our Approach
Technologies
Manufacturing
Publications
Pipeline
Pipeline
Autologous CAR-T
Allogeneic CAR-T
Expanded Access
Investors
Announcements
Corporate Governance
Corporate Deck & Presentations
Webcasts
Presentations
Financial Reports
Listing Documents
IR Contact
Newsroom
Careers
Join Us
Contact Us
Newsroom
Home
-
Newsroom
-
Search News
20
Jan 2025
CARsgen’s Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
Jan 20, 2025
13
Jan 2025
CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
Jan 13, 2025
31
Dec 2024
CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy
Dec 31, 2024
30
Dec 2024
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
Dec 30, 2024
23
Dec 2024
CARsgen’s Allogeneic CAR-T Product Developed on the THANK-u Plus Platform Administers First Dose in an IIT
Dec 23, 2024
06
Nov 2024
CARsgen
®
to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress
Nov 06, 2024
01
Nov 2024
CARsgen
®
U.S. Clinical Holds Lifted by FDA
Nov 01, 2024
09
Oct 2024
CARsgen
®
Submitted Application to Request Lifting Clinical Holds to FDA
Oct 09, 2024
29
Aug 2024
CARsgen
®
Announces 2024 Interim Results
Aug 29, 2024
19
Aug 2024
CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel)
Aug 19, 2024
1
2
...
9